Deciphering the genetic profiles of responders and resistant tumors to immune checkpoint inhibitors using tumor and plasma cfDNA exome sequencing
Funding: CIBERONC WM (€ 50.000) and Swiss Bridge Award (€ 200.000, PI Rodrigo Toledo, PhD)
We have been using whole exome-sequencing of germline DNA (gDNA), tumor DNA (tDNA – when available), and plasma cell-free DNA (cfDNA) to investigate the influence of tumor mutation load, type of mutation, tumor mutation signatures, and mutations in immune-related genes in the cohort of metastatic cancer patients (Pan-Cancer) treated with cancer immunotherapy.
Check-out detailed information, methods, specific aims, inclusion/exclusion criteria, and preliminary results of 50 patients